Smasse, stop with the "manipulation" is preventing ADXS from being worth $1B-$2B. Nonsense. Are there traders and short sellers who are holding back the pps to some extent? I suspect there are, but not on the order of 3X-6X the current market cap. That's just silly.
I've stated the reason for ADXS's market cap: their technology is an arcane outlier. Few scientists believe it can deliver an effective, safe immune response to cancer cells. Only Aduro and Advaxis are pursuing it. Anyone with a PhD in this area thinks the listeria vector concept is cumbersome and hard to control. Investment analysts do not study it because the benefit from doing so is so small (you get to understand two companies). If analysts learn all about viral vectors and CAR-T they get to understand dozens of companies, so that's where they put their focus. If few analysts follow ADXS, then few institutions will invest in it because they don't have the information they need to make an informed investment decision.
The VERY FACT that ADXS has a low market cap should be EXACTLY the reason you are invested in it. Why? Because that situation says you've found something before lots of other people understand the value of what you've discovered. When will other's discover this value? I've said this before: a successful Ph3 (or two) on AXAL for cervical cancer and numerous (3-4-5) successful Ph1 and Ph2 trials using the Lm platform (some of them combo trials).
THOSE RESULTS are 12-24 months in the future. Once AXAL is fully validated, ADXS might be worth $1B-$2B (cervical is no where's near a $6B market at the price AXAL will be sold). Once the Lm platform is shown to have broad applicability to various cancers, now we're talking $6B+ valuation. But, that's not today, nor in 6-12 months. Maybe in 24 months; I hope within 36 months.
